JoseCaetanoVillasboas BisnetoMD

Senior Associate Consultant / Assistant Professor of Medicine and Oncology

Dr. Villasboas Bisneto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2013 - 2017
University of Miami/Jackson Health SystemResidency, Internal Medicine, 2009 - 2013
Federal University of Bahia Faculty of MedicineClass of 2008, MD

PubMed

32 citations
Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?
Omran Saifi, William G Breen, Scott C Lester, William G Rule, Bradley Stish
Radiotherapy and Oncology. 2022-01-01
78 citations
The use of pembrolizumab for the treatment of metastatic uveal melanoma.
Lisa A. Kottschade, Robert R. McWilliams, Svetomir N. Markovic, Matthew S. Block, Jose Villasboas Bisneto
Melanoma Research. 2016-06-01
4 citations
Predictors of short-term survival in Waldenström Macroglobulinemia
Gordon Ruan, Saurabh Zanwar, Jithma P. Abeykoon, Stephen M. Ansell, Morie A. Gertz
Leukemia & Lymphoma. 2020-07-14

Abstracts/Posters

Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
Jose Villasboas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...
Jose Villasboas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tumor ADAM10/ADAM17-Mediated PD-L1 Loss May Predict Poor Outcomes in Diffuse Large B Cell Lymphoma
Jose Villasboas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Mass Cytometry Identifies a Novel Signature for Myeloid-Derived Suppressor-Cells in WaldenstromÍs Macroglobulinemia
Jose Villasboas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relap...
2019 ASCO Annual Meeting - 6/1/2019